Goldman Sachs
INAB icon

Goldman Sachs’s IN8bio INAB Stock Holding History

Goldman Sachs’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-340
Closed -$2.62K – 6229
2024
Q4 		$2.62K Buy
+340
New +$2.99K ﹤0.01% 5970
2024
Q2 		– Sell
-387
Closed -$13.7K – 5783
2024
Q1 		$13.7K Buy
+387
New +$14.6K ﹤0.01% 5418

Other funds holding INAB

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's INAB Position: Q1 2025 in Review

Goldman Sachs sold out of IN8bio (INAB) in Q1 2025, closing a stake of 340 shares — an estimated $2.62K sold.

Goldman Sachs first reported a position in INAB in Q1 2024 and held it in 2 quarters. The position peaked at $13.7K in Q1 2024. 28 funds tracked by Wall St. Rank hold INAB as of Q1 2025.

  • Goldman Sachs reported no remaining IN8bio position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 340 IN8bio shares in Q1 2025, an estimated $2.62K.
  • Goldman Sachs first reported a position in IN8bio in Q1 2024 and held it in 2 quarters.
  • Goldman Sachs's IN8bio position peaked at $13.7K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held IN8bio as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.